LEO 90100

DRUG7 trials

Sponsors

LEO Pharma

Conditions

Psoriasis VulgarisStable Plaque Psoriasis

Phase 1

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

CompletedNCT01935869

LEO PharmaPsoriasis Vulgaris

Start: 2013-08-31End: 2013-12-31Updated: 2025-02-24

Phase 2

LEO 90100 in the Treatment of Psoriasis Vulgaris

CompletedNCT01536938

LEO PharmaPsoriasis Vulgaris

Start: 2012-05-31End: 2012-11-30Updated: 2025-03-07

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

CompletedNCT01536886

LEO PharmaPsoriasis Vulgaris

Start: 2012-05-31End: 2012-11-30Updated: 2025-03-07

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

CompletedNCT01600222

LEO PharmaPsoriasis Vulgaris

Start: 2012-05-31End: 2013-05-31Updated: 2025-03-07

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

CompletedNCT02387853

LEO PharmaPsoriasis Vulgaris

Start: 2016-03-31End: 2018-03-28Updated: 2025-03-10

Phase 3

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

CompletedNCT01866163

LEO PharmaPsoriasis Vulgaris

Start: 2013-06-30End: 2013-11-30Updated: 2025-03-10

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

CompletedNCT05919082

LEO PharmaStable Plaque Psoriasis

Start: 2023-06-21End: 2024-03-05Updated: 2026-04-06

Related Papers

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial.

PubMed2026-05-03

Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials

Journal of Drugs in Dermatology2021-07-011 citations

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials.

2020-08-123 citations

Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data

PubMed2020-08-014 citations

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.

2020-05-169 citations

Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

2020-02-198 citations

Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis

Journal of Drugs in Dermatology2020-01-012 citations

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Journal of the European Academy of Dermatology and Venereology2018-12-0623 citations

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.

2016-10-064 citations